Recombinant CD274 (Durvalumab Biosimilar) anticorps

N° du produit ABIN7795090

Cet anticorps anti-CD274 (Durvalumab Biosimilar) est un anticorps Humanized Monoclonal détectant CD274 (Durvalumab Biosimilar) dans FACS et in vivo. Adapté pour Humain.

Aperçu rapide pour Recombinant CD274 (Durvalumab Biosimilar) anticorps (ABIN7795090)

Antigène: CD274 (Durvalumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD274 (Durvalumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD274 (Durvalumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Durvalumab Biosimilar, PD-L1 Monoclonal Antibody

Attributs du produit: Durvalumab Biosimilar uses the same protein sequences as the therapeutic antibody durvalumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD1 (CD279, programmed death 1). Durvalumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1). Durvalumab completely blocks the binding of PDL1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab is an anticancer antibody that works to promote the antitumor response mediated by immune cells. By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation, enhancing detection and ablation of tumor cells. In in vitro assays, durvalumab inhibited the activity of PD-L1 in a concentration-dependent manner. In co-engrafted human tumor and immune cell xenograft mouse models, durvalumab was effective in decreasing tumor size. Durvalumab does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human PD-L1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD274 (Durvalumab Biosimilar)

Antigène: CD274 (Durvalumab Biosimilar)

Autre désignation: Durvalumab Biosimilar

Classe de substances: Biosimilar